Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

1. Moreno, V.
2. Sepulveda, J.M.
3. Vieito, M.
4. Hernández-Guerrero, T.
5. Doger, B.
6. Saavedra, O.
7. Ferrero, O.
8. Sarmiento, R.
9. Arias, M.
10. De Alvaro, J.
11. Di Martino, J.
12. Zuraek, M.
13. Sanchez-Pérez, T.
14. Aronchik, I.
15. Filvaroff, E.H.
16. Lamba, M.
17. Hanna, B.
18. Nikolova, Z.
19. Braña, I.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.ANNONC.2020.03.294 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus